Cargando…

Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds

Type 2 diabetes (T2D) is a metabolic disorder where insulin-sensitive tissues show reduced sensitivity towards insulin and a decreased glucose uptake (GU), which leads to hyperglycaemia. Peroxisome proliferator-activated receptor (PPAR)γ plays an important role in lipid and glucose homeostasis and i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Porskjær Christensen, Lars, Bahij El-Houri, Rime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222920/ https://www.ncbi.nlm.nih.gov/pubmed/30248999 http://dx.doi.org/10.3390/molecules23102431

Ejemplares similares

Dietary Polyacetylenic Oxylipins Falcarinol and Falcarindiol Prevent Inflammation and Colorectal Neoplastic Transformation: A Mechanistic and Dose-Response Study in A Rat Model
por: Kobaek-Larsen, Morten, et al.
Publicado: (2019)

Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes
por: Yasmin, Sabina, et al.
Publicado: (2017)

Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists
por: Najmi, Asim, et al.
Publicado: (2023)

Bioactive C(17) and C(18) Acetylenic Oxylipins from Terrestrial Plants as Potential Lead Compounds for Anticancer Drug Development
por: Christensen, Lars Porskjær
Publicado: (2020)

Falcarindiol Purified From Carrots Leads to Elevated Levels of Lipid Droplets and Upregulation of Peroxisome Proliferator-Activated Receptor-γ Gene Expression in Cellular Models
por: Andersen, Camilla Bertel, et al.
Publicado: (2020)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Targeting PPAR-γ to design and synthesize antidiabetic thiazolidines
por: Sawant, Ramesh L., et al.
Publicado: (2018)

PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer
por: Ballav, Sangeeta, et al.
Publicado: (2022)

Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
por: Ayza, Muluken Altaye, et al.
Publicado: (2020)

Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals
por: Niu, Ho-Shan, et al.
Publicado: (2015)

Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γ Agonist against MPTP
por: Swanson, Christine R., et al.
Publicado: (2013)

Structural and Dynamic Elucidation of a Non-acid PPARγ Partial Agonist: SR1988
por: Frkic, Rebecca L., et al.
Publicado: (2018)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists
por: Liberato, Marcelo Vizoná, et al.
Publicado: (2012)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

Novel Podophyllotoxin Derivatives as Partial PPARγ Agonists and their Effects on Insulin Resistance and Type 2 Diabetes
por: Zhang, Xiangming, et al.
Publicado: (2016)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
por: Harnchoowong, Sarawin, et al.
Publicado: (2017)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

A compound-based proteomic approach discloses 15-ketoatractyligenin methyl ester as a new PPARγ partial agonist with anti-proliferative ability
por: Vasaturo, Michele, et al.
Publicado: (2017)

Screening of saponins and sapogenins from Medicago species as potential PPARγ agonists and X-ray structure of the complex PPARγ/caulophyllogenin
por: Montanari, Roberta, et al.
Publicado: (2016)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARα + γ Agonists
por: Oleksiewicz, Martin B., et al.
Publicado: (2008)

CMHX008, a PPARγ partial agonist, enhances insulin sensitivity with minor influences on bone loss
por: Hou, Yi, et al.
Publicado: (2018)

Chiral phenoxyacetic acid analogues inhibit colon cancer cell proliferation acting as PPARγ partial agonists
por: Sabatino, Lina, et al.
Publicado: (2019)

MBX-102/JNJ39659100, a Novel Non-TZD Selective Partial PPAR-γ Agonist Lowers Triglyceride Independently of PPAR-α Activation
por: Chandalia, Apurva, et al.
Publicado: (2009)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
por: Jia, Zhanjun, et al.
Publicado: (2014)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

Dual PPAR α/γ Agonists: Continuing Cardiac Concerns
por: Balachandran, Karthik
Publicado: (2019)

Partial Agonist, Telmisartan, Maintains PPARγ Serine 112 Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass
por: Kolli, Vipula, et al.
Publicado: (2014)

Synthesis and biological evaluation of dihydropyrano-[2,3-c]pyrazoles as a new class of PPARγ partial agonists
por: Qvortrup, Katrine, et al.
Publicado: (2017)

Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs
por: Lee, Min A, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i16q35ebtfkrgiuqbf6qpihd2j